Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised and immediately sold 10,250 shares on March 5, 2026, generating approximately $347,000 in proceeds. The sale represented 100% of her direct common stock holdings, though she retains 50,935 options. The transaction was pre-scheduled under a 10b5-1 plan adopted in June 2025, suggesting a planned move rather than a reactive decision. Sionna has two clinical trials with topline data expected mid-2026 and maintains $310.3 million in cash runway through 2028.

OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatments, reported positive phase 1 results in June and began phase 2 trials in October, with top-line results expected mid-2026.

Sionna Therapeutics initiated a Phase 2a clinical trial evaluating SION-719, a novel NBD1 stabilizer, as an addition to standard cystic fibrosis treatment Trikafta. The trial aims to assess safety, tolerability, and potential improvement in CFTR protein function, with topline data expected in mid-2026.

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, will participate in two upcoming investor conferences in September 2025, presenting their research on CFTR protein function normalization.

Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.